Key result
Everolimus-eluting BVS in STEMI shows ~9% early MACE without stent thrombosis.
Why the study?
There were no data on the use of everolimus-eluting bioresorbable vascular scaffold (BVS) in patients with STEMI undergoing primary PCI.
Is everolimus-eluting bioresorbable vascular scaffold (BVS) implantation safe in patients with STEMI undergoing primary PCI?
Observational (n=11)
No
Is everolimus-eluting bioresorbable vascular scaffold (BVS) implantation safe in patients with STEMI undergoing primary PCI?
Everolimus-eluting bioresorbable vascular scaffold implantation appears feasible and safe in the short term for STEMI patients undergoing primary PCI, based on a small initial case series.
BVS feasible in small STEMI cohort; leaves open whether it improves outcomes versus metallic stents in primary PCI.
AIMS: Recent studies have demonstrated favourable clinical outcomes for the everolimus-eluting bioresorbable vascular scaffold (BVS) ABSORB™ in patients with stable coronary artery disease. There are currently no data on its use in patients with ST-segment elevation myocardial infarction (STEMI). We assessed the safety and impact of BVS in the setting of primary percutaneous coronary intervention (PCI) in patients presenting with STEMI to our institution. METHODS AND RESULTS: A total of 11 patients who underwent primary PCI with intent for BVS implantation between October 2012 and April 2013 at our institution were included. Median follow-up period was 53.0 ± 45.9 days. One patient presented to the hospital with cardiogenic shock and subsequently died. The other 10 patients did not have any major adverse cardiac events (MACE). There were no acute or subacute stent thromboses at short-term follow-up. CONCLUSIONS: These are the first real-world data using BVS in patients with STEMI. The ABSORB™ BVS may be safely used in patients with STEMI undergoing primary PCI with favourable short-term outcome.
No takes yet. Share an insight, caveat, or question.
Kajiya et al. (2013) conducted an observational in ST-segment elevation myocardial infarction (STEMI) (n=11). Everolimus-eluting bioresorbable vascular scaffold (BVS) was evaluated on Major adverse cardiac events (MACE). Everolimus-eluting bioresorbable vascular scaffold implantation in 11 STEMI patients resulted in 1 death and no other major adverse cardiac events or stent thromboses at a median of 53 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: